Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD3 | Q9NY59 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.30 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5633206 | 0.80 | SMPD3 (0.35) | SMPD3 | |
| SCHEMBL5634860 | 0.79 | ALDH1A1 (0.38) | ALDH1A1HPGDHSD17B10GAAMAPT | |
| Hydrochloric Acid SCHEMBL8566583 | 0.77 | ALDH1A1 (0.37) | ALDH1A1HPGDHSD17B10GAAMAPT | |
| SCHEMBL12432819 | 0.72 | ALDH1A1 (0.38) | SMPD3ALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL2314068 | 0.70 | ALDH1A1 (0.37) | SMPD3ALDH1A1HPGDHSD17B10MAPT | |
| SCHEMBL2313912 | 0.69 | ALDH1A1 (0.36) | ALDH1A1HPGDHSD17B10MAPTADORA3 | |
| SCHEMBL2403951 | 0.68 | DHFR (0.48) | ALDH1A1HPGDHSD17B10GAAMAPT | |
| Bromide SCHEMBL9099637 | 0.67 | DHFR (0.47) | ALDH1A1HPGDHSD17B10GAAMAPT | |
| Hydrochloric Acid SCHEMBL9081198 | 0.67 | DHFR (0.47) | ALDH1A1HPGDHSD17B10GAAMAPT | |
| SCHEMBL25103902 | 0.65 | HTR6 (0.34) | ALDH1A1HPGDHSD17B10GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7196196-B2 | Substituted imidazo[1, 2-a]-5,6,7,8-tetrahydropyridine-8-ones, method for their production and the use thereof for producing imidazo[1,2-a]pyridines | BASF AKTIENGESELLSCHAFT (DE) | 2007-03-27 | — | — | US | disclosed |
| US-20050020620-A1 | Substituted imidazo[1, 2-a]-5,6,7,8-tetrahydropyridine-8-ones, method for their production and the use thereof for producing imidazo[1,2-a]pyridines | BASF AKTIENGESELLSCHAFT (DE) | 2005-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020620-A1 | Substituted imidazo[1, 2-a]-5,6,7,8-tetrahydropyridine-8-ones, method for their production and the use thereof for producing imidazo[1,2-a]pyridines | BTN3A1, DHPS, NISCH | SMPD3 4780/4885ALDH1A1 498/4885HPGD 294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.